A decision has been issued under the Tennis Anti-Doping Programme (the "Programme") that Beatriz Haddad Maia has committed an Anti-Doping Rule Violation under Article 2.1. That decision imposed a period of ineligibility of ten months, commencing on 22 July 2019.
Ms. Maia, a 23-year-old player from Brazil, provided a urine sample on 4 June 2019 in association with her participation in the WTA Croatia Bol Open held in Bol, Croatia from 3 June to 9 June 2019. That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain SARM S-22 (Ostarine or Enobosarm) and SARM LGD-4033 (Ligandrol) metabolite. SARM S-22 and SARM LDG-4033 are Non-Specified substances, which are prohibited under category S1 of the 2019 WADA Prohibited List (Anabolic Agents), and therefore are also prohibited under the Programme.
Ms. Maia was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was provisionally suspended on 22 July 2019. The ITF accepted Ms. Maia’s explanation as to how the SARM S-22 and SARM LDG-4033 entered her system and that she bore No Significant Fault or Negligence for her violation. Ms. Maia was entitled to her period of ineligibility being back-dated to start on the date on which she was provisionally suspended.
This is Ms. Maia’s first Anti-Doping Rule Violation. The decision determines that: (1) Ms. Maia has committed a violation of the Programme; (2) she must serve a period of ineligibility of ten months; and (3) that period of ineligibility is back-dated to start on 22 July 2019, and so ending at midnight on 21 May 2020. In accordance with Programme articles 9.1 and 10.8, all ranking points and prize money obtained by Ms. Maia at the Event and subsequent events are disqualified.